ArticleCancers2020
Nanoemulsions as Delivery Systems for Poly-Chemotherapy Aiming at Melanoma Treatment.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 52 citations in OpenAlex.
- Nanotechnology integration in oncology for advanced nanoparticle based strategies in targeted cancer diagnosis and treatment.Discover nano · 2026Review
- Improving the bioavailability of nintedanib by formulating inhalable ufasomes as a targeted therapy for non-small cell lung cancer.International journal of pharmaceutics: X · 2026Article
- Exploring Anti-Neoplastic Activity of Chitosan Nanobubbles Decorated with ICOS-Fc and Loaded with Paclitaxel in a Human and Murine Model of Melanoma.Pharmaceutics · 2025Article
- Recent advancements in nanoparticles for cancer treatment.Medical oncology (Northwood, London, England) · 2025Review
- Nanoemulsions in Skin Cancer Therapy: A Promising Frontier.Current pharmaceutical biotechnology · 2025Review
- Herbal based nanoparticles as a possible and potential treatment of cancer: a review.Exploration of targeted anti-tumor therapy · 2025Review
- Insight into the Recent Developments of Nanoparticles in Treatment of Cancer and Neuro-Degenerative Disease: A Review.Current topics in medicinal chemistry · 2025Review
- Concanavalin a Grafted Nanoemulsions for Nasal Delivery: Preliminary Studies with Fluorescently Labelled Formulations.Materials (Basel, Switzerland) · 2024Article
- In-vivo Toxicity Evaluation of 3-(2-(3,4 dimethoxyphenyl)-2 oxoethylidene) Indolin-2-one (RAJI) in Zebrafish and Mice Model.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Green Solid Lipid Nanoparticles by Fatty Acid Coacervation: An Innovative Nasal Delivery Tool for Drugs Targeting Cerebrovascular and Neurological Diseases.Pharmaceutics · 2024Article
- Cell Membrane Fragment-Wrapped Parenteral Nanoemulsions: A New Drug Delivery Tool to Target Gliomas.Cells · 2024Article
- Alendronate-Grafted Nanoemulsions for Bone-Targeted Vincristine Delivery: Preliminary Studies on Cell and Animal Models.Biomolecules · 2024Article
- Nanomaterials in Targeting Cancer Cells with Nanotherapeutics: Transitioning Towards Responsive Systems.Current pharmaceutical design · 2024Review
- Use of Total Parenteral Nutrition (TPN) as a Vehicle for Drug Delivery.Current drug targets · 2024Review
- Metastatic Melanoma: A Preclinical Model Standardization and Development of a Chitosan-Coated Nanoemulsion Containing Temozolomide to Treat Brain Metastasis.Cellular and molecular neurobiology · 2023Article
- Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma.Antioxidants (Basel, Switzerland) · 2023Article
- Surface Functionalised Parenteral Nanoemulsions for Active and Homotypic Targeting to Melanoma.Pharmaceutics · 2023Article
- Exploiting Nanomedicine for Cancer Polychemotherapy: Recent Advances and Clinical Applications.Pharmaceutics · 2023Review
- Multidrug-Loaded Lipid Nanoemulsions for the Combinatorial Treatment of Cerebral Cavernous Malformation Disease.Biomedicines · 2023Article
- Parenteral Nanoemulsions Loaded with Combined Immuno- and Chemo-Therapy for Melanoma Treatment.Nanomaterials (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Chiara DianzaniDepartment of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin, Italy.
Chiara MongeDepartment of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin, Italy.
Gianluca MiglioDepartment of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin, Italy.
Loredana SerpeDepartment of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin, Italy.ORCID 0000-0002-1080-0322
Katia MartinaDepartment of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin, Italy.ORCID 0000-0003-2256-5021
Luigi CangemiDepartment of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin, Italy.
Chiara FerrarisDepartment of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin, Italy.
Silvia MiolettiDepartment of Veterinary Sciences, University of Turin, Largo Paolo Braccini 2, 10095 Grugliasco, Italy.
Sara OsellaSan Giovanni Bosco Hospital, Piazza del Donatore di Sangue 3, 10154 Turin, Italy.
Casimiro Luca GigliottiDepartment of Health Sciences and Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont (UPO), via Solaroli 17, 28100 Novara, Italy.ORCID 0000-0002-3127-5686
Elena BoggioDepartment of Health Sciences and Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont (UPO), via Solaroli 17, 28100 Novara, Italy.ORCID 0000-0003-2700-3597
Nausicaa ClementeDepartment of Health Sciences and Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont (UPO), via Solaroli 17, 28100 Novara, Italy.ORCID 0000-0002-9860-0148
Umberto DianzaniDepartment of Health Sciences and Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont (UPO), via Solaroli 17, 28100 Novara, Italy.
Luigi BattagliaDepartment of Drug Science and Technology, University of Turin, via Pietro Giuria 9, 10125 Turin, Italy.ORCID 0000-0002-5081-3638
University of Turin · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITOspedale San Giovanni Bosco · IT
Funding
Associazione Italiana per la Ricerca sul Cancro IG 20714Fondazione CRT project n. 2019.2252Ministero dell'Istruzione, dell'Università e della Ricerca FFABR 2017Università degli Studi di Torino Ricerca Locale 2016-2017
Abstract
PubMed holds no abstract for this paper.
Indexed as
bevacizumabIntralipid®melanomananoemulsionsrapamycintemozolomide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.